Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Progressive or Metastatic Bone or Soft Tissue Sarcomas
NCT00767819Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of everolimus in bone sarcoma, soft tissue sarcoma (STS), gastrointestinal stromal tumor (GIST), alveolar soft part sarcoma (ASPS), sponsored by Novartis. Started Mar 2008; status: completed.
02
Drugs
everolimus
03
Conditions
bone sarcomasoft tissue sarcoma (STS)gastrointestinal stromal tumor (GIST)alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT00767819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00767819.